Sign up for Table of Contents Alerts.
Email this page
Print this page
Report
Lap2α Expression is Controlled by E2F and Deregulated in Various Human Tumors
Paola Parise, Giacomo Finocchiaro, Barabara Masciadri, Micaela Quarto, Stefanie Francois, Francesco Mancuso and Heiko Muller
volume 5 | issue 12
15 june 2006Pages: 1331 - 1341
We now provide open access to journal articles published online for one year or more. This article may be downloaded at the following link:
Download PDF If the document does not open, please right-click on the link (control-click on a Macintosh) and select the option to save the file to disk.
Deregulation of the retinoblastoma (pRB) tumor suppressor pathway is frequently observed in human cancer and associated with aberrant activity of E2F transcription factors. We have performed microarray based analysis with the aim of identifying potential downstream mediators of the tumor suppressing activity of pRB. Here we report that the expression of LAP2 (lamina-associated polypeptide 2) is under direct control of E2F transcription factors. Chromatin immunoprecipitation assays show that the LAP2 promoter is bound by endogenous E2F in vivo. The LAP2 promoter is transactivated by ectopically expressed E2F and mutation of E2F binding sites eliminates this effect. We studied the expression level of LAP2α in human tumors by tissue microarray analysis and found LAP2α over expression in a significant percentage of primary larynx, lung, stomach, breast, and colon cancer tissues. In agreement with its regulation by E2F, LAP2α over expression in primary tumors was found to be correlated with tumor proliferation rate.
We now provide open access to journal articles published online for one year or more. This article may be downloaded at the following link:
Download PDF If the document does not open, please right-click on the link (control-click on a Macintosh) and select the option to save the file to disk.